Adaptive Biotech, Janssen ally in diagnostics deal
Executive Summary
Adaptive Biotechnologies Corp. will use its next-generation sequencing-based clonoSEQ assay to measure minimal residual disease (MRD) in multiple myeloma patients who've been treated with Janssen Biotech Inc.'s Darzalex (daratumumab).
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Drug Discovery Tools
- Pharmacogenetics-Pharmacogenomics
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice